文章：

复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）的分子通路与靶向治疗

Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

原文发布日期：11 July 2025

DOI: 10.3390/cancers17142314

类型: Article

开放获取: 是

英文摘要：

There have been multiple approved agents for relapsed/refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) over the last 8 years. The majority of these therapies act on specific signaling pathways in malignant B-cells. These signaling pathways stem from the B-cell receptor (BCR), Toll-Like Receptor (TLR), PI3K/AKT/mTOR, BCL-2, and XPO-1. In addition, novel therapies that target extracellular proteins (CD19, CD20, CD30, ROR1, and PD-1) have been developed. The purpose of this review is to discuss the various therapies that target these pathways and highlight the success and shortcomings of these novel agents.

摘要翻译： 

在过去八年中，针对复发/难治性弥漫性大B细胞淋巴瘤已有多种获批药物。这些疗法大多作用于恶性B细胞中的特定信号通路，主要包括B细胞受体、Toll样受体、PI3K/AKT/mTOR通路、BCL-2及XPO-1等信号传导途径。此外，针对细胞外蛋白（CD19、CD20、CD30、ROR1和PD-1）的新型疗法也相继问世。本文旨在系统评述针对这些信号通路的各类治疗策略，并重点分析这些新型药物的临床成效与现存局限。

原文链接：

Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)